Edgewise Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Edgewise completed the sale of its sevasemten program and muscular dystrophy business to Servier in July 2026, receiving $1.396 billion in upfront cash proceeds and recognizing a $1.348 billion gain in Q3 2026. The company's cash position increased from $530.1 million (Dec 2025) to $1,743.9 million (Sep 2026). Core pipeline remains on track: EDG-7500 Phase 3 for HCM expected to initiate by year-end 2026; EDG-15400 Phase 2 EQUINOX-HFpEF trial dosed first patient. Q3 R&D expenses were $31.6 million (down from $37.5 million YoY due to sevasemten sale), while G&A expenses increased to $14.6 million from $9.4 million.
Why this rating
Material capital infusion (>130% of prior cash) de-risks operations, but divestiture narrows focus. Strong for pipeline execution; offsets near-term clinical development spend.
Price action (we called it positive)
before filing · preread $37.53 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.